RDY — Dr. Reddy's Laboratories Limited

Summary of Dr. Reddy's Laboratories Q4 and Full Year FY '26 Earnings Call

1. Key Financial Results and Metrics:

• Q4 FY '26 Revenue: Adjusted revenue of INR 7,969 crores (USD 849 million), down 6% YoY and 9% QoQ, primarily due to lower lenalidomide sales.
• Full Year FY '26 Revenue: INR 34,046 crores (USD 3.63 billion), representing a growth of 4.6%.
• Adjusted Profit Before Tax (PBT): INR 994 crores for Q4, INR 6,463 crores for FY '26, with margins of 12.5% and 19%, respectively.
• Net Profit: INR 220 crores (USD 23 million) for Q4; INR 4,285 crores (USD 457 million) for FY '26, with a margin of 13%.
• Gross Margin: 48% for Q4 (down 760 bps YoY) and 53.5% for FY '26 (down 498 bps YoY).
• R&D Spend: INR 541 crores for Q4 (down 26% YoY) and INR 2,385 crores for FY '26 (down 13% YoY).
• CapEx: INR 438 crores for Q4 and INR 2,302 crores for FY '26.

2. Strategic Updates and Business Highlights:

• The company is focusing on strengthening its base business while investing in growth drivers like peptides, biosimilars, and consumer health.
• Regulatory approval for semaglutide injection in Canada and India, with plans to launch the oral version.
• Progress on key pipeline assets, including abatacept biosimilar, with FDA acceptance for review.
• Successful integration of the NRT Consumer Healthcare business.
• Recognition for sustainability efforts, achieving a gold medal from EcoVadis.

3. Forward Guidance and Outlook:

• The company anticipates sustaining double-digit growth in its base business for FY '27.
• Expected gross margins to improve above 50% in FY '27, driven by new product launches and cost efficiencies.
• SG&A spending is projected to remain at similar levels to FY '26, supporting growth initiatives.
• Effective tax rate expected to be between 24% and 25% for FY '27.

4. Bad News, Challenges, or Points of Concern:

• Significant revenue reduction due to a shelf-stock adjustment related to lenalidomide, amounting to INR 453 crores.
• Declining gross margins due to lower sales of lenalidomide and price erosion in unbranded generics.
• The North American market faced challenges with a 40% decline in revenue due to lenalidomide issues, impacting overall performance.
• Impairments related to R&D programs and potential VAT liabilities raised concerns over future profitability.

5. Notable Q&A Insights:

• Management acknowledged the unexpected size of the shelf-stock adjustment for lenalidomide, attributing it to customer planning issues.
• Competitive landscape for semaglutide in Canada is expected to stabilize initially with limited players, but more competition is anticipated in the future.
• The company plans to maintain a double-digit growth trajectory in North America, excluding lenalidomide, driven by new product launches.
• R&D spending is expected to decrease as the company shifts focus from in-house development to partnerships, enhancing productivity and reducing costs.
• The oral version of semaglutide is expected to perform well in emerging markets, with pricing strategies set to be competitive against innovator products.

Overall, Dr. Reddy's Laboratories demonstrated resilience in its core business despite facing headwinds from specific product sales and regulatory challenges, while maintaining a strategic focus on innovation and market expansion.